- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Zinc may shorten common cold
Zinc, in lozenge or syrup form, is beneficial in reducing the duration and severity of the common cold in healthy people, when taken within at least 24 hours of onset of symptoms, according to a new report published in the Cochran Library.
Zinc, in lozenge or syrup form, is beneficial in reducing the duration and severity of the common cold in healthy people, when taken within at least 24 hours of onset of symptoms, according to a new report published in the Cochran Library.
Zinc is said to inhibit rhinoviral replication, and has been tested in trials for treatment of the common cold. The review identified 15 randomized controlled trials enrolling 1,360 participants aged 1 to 65 years, comparing zinc with placebo.
Researchers in India found that people who took zinc within 24 hours of symptom onset were over their colds about 1 day sooner than people who took placebos. They also found that people taking zinc are less likely to have persistence in their cold symptoms beyond 7 days of treatment. Zinc supplementation for at least 5 months reduces incidence, school absenteeism, and prescription of antibiotics for children with the common cold.Adverse events experienced by people taking zinc lozenges include bad taste and nausea.
As there are no studies in participants in whom common cold symptoms might be troublesome (for example, those with underlying chronic illness, immunodeficiency, and asthma), the use of zinc currently cannot be recommended for them.
The researchers acknowledge that before making a general recommendation for zinc in the treatment of the common cold, given the variability in the populations studied (no studies from low- or middle-income countries), dose, formulation, and duration of zinc used in the included studies, more research is needed to address these variabilities and determine the optimal duration of treatment, as well as the dosage and formulations of zinc that will produce clinical benefits without increasing adverse effects.
“Anything that might help reduce the onset of a full-blown cold sounds like something worth trying,” Peggy C. Frank, CEO of Frank Public Relations Worldwide, a healthcare public relations firm in Los Angeles, told Formulary. “The possibility to reduce absenteeism from school and the workplace makes this study worthy of embracing. It might also be a great time to review protocols for disinfecting the workplace and schools to help thwart the airborne virus repeat performances.”
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
